SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 61.9% in December

SciSparc Ltd. (NASDAQ:SPRC) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 155,400 shares, a growth of 61.9% from the November 30th total of 96,000 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily trading volume, of 725,400 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in SciSparc stock. Renaissance Technologies LLC acquired a new stake in shares of SciSparc Ltd. (NASDAQ:SPRC) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned 5.59% of SciSparc as of its most recent SEC filing. Institutional investors own 25.06% of the company’s stock.

SciSparc Price Performance

SPRC stock traded down $0.02 during mid-day trading on Friday, reaching $0.48. The company had a trading volume of 6,766,140 shares, compared to its average volume of 2,471,099. The firm has a 50 day moving average of $0.24 and a 200 day moving average of $0.40. SciSparc has a 12 month low of $0.20 and a 12 month high of $6.78.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.